Navigation Links
BD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011
Date:7/26/2011

FRANKLIN LAKES, N.J., July 26, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, in accordance with its long-term succession planning, it has elected Vincent A. Forlenza as Chief Executive Officer and President, effective October 1, 2011. Mr. Forlenza will also become a member of the Board at that time. Also effective October 1, current BD Chairman and Chief Executive Officer Edward J. Ludwig will serve as executive Chairman of the Board through June 2012.

"This change in leadership is the result of the Board's focus on succession planning that began in 2008 as part of our corporate governance practices," said Henry P. Becton, Jr., BD's Lead Director.  "The selection of an excellent internal candidate to replace Ed demonstrates the strength of executive leadership development at BD."

Mr. Forlenza, 58, joined BD in 1980. His BD career has spanned strategic planning, marketing, general management of several business units and executive leadership.  His prior roles include service in all three business segments (BD Medical, BD Diagnostics and BD Biosciences) as well as in strategy development and overseas roles. He was named Executive Vice President in 2006 and President in 2009; he assumed the additional role of Chief Operating Officer in July 2010.

"Over the last 30 years, Vince has distinguished himself as a leader. He has an outstanding track record running businesses, international operations, technology and business development," said Mr. Ludwig. "His broad array of achievements has prepared and eminently qualified him to lead BD to the next level as the Company continues its journey to greatness."

Mr. Ludwig, 60, joined BD in 1979. He became President in May 1999, Chief Executive Officer in January 2000 and Chairman in February 2002. Over the last 12 years, the Company has more than doubled its revenues, more than tripled its net income and nearly tripled its market cap, and it ranks in the top third among its peer group for total shareholder return for that period. During the same period, BD has invested $3.6 billion in R&D and $5.1 billion in capital expansions, and revenues derived from sales outside of the United States have grown from 43 percent to 57 percent today. And, thousands of BD associates have benefited from executive training programs – a key initiative created during Mr. Ludwig's inaugural year as CEO.

"On behalf of BD, its shareholders, associates and the Board of Directors, I want to thank Ed for the extraordinary leadership he has provided during his time as CEO.  We are pleased that Ed will continue to provide his insight and counsel as Vince transitions to his new role," added Mr. Becton.  

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications
201-310-2493 (c); 201-847-5369 (o)
colleen_white@bd.com

Monique N. Dolecki, Investor Relations – 201-847-5453
Monique_dolecki@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Silence Therapeutics Announces Board Changes
11. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):